Market closedADR

Adaptimmune Therapeutics/$ADAP

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Ticker

$ADAP
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Abingdon, United Kingdom

Employees

449
Website
www.adaptimmune.com

ADAP Metrics

BasicAdvanced
$152M
-
-$0.18
2.25
-

$152M

2.25

$2.05

$0.53

2.5M

3.848

3.541

87.912

93.132

-23.09%

-7.68%

-52.96%

0.834

1.9

2.01

-2.604

146.27%

-65.48%

203.94%

-43.42%

What the Analysts think about ADAP

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Adaptimmune Therapeutics stock.

ADAP Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ADAP Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ADAP News

AllArticlesVideos
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Newsfile Corp·2 days ago
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Newsfile Corp·4 weeks ago
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADAP

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adaptimmune Therapeutics stock?

Adaptimmune Therapeutics (ADAP) has a market cap of $152M as of January 15, 2025.

What is the P/E ratio for Adaptimmune Therapeutics stock?

The price to earnings (P/E) ratio for Adaptimmune Therapeutics (ADAP) stock is 0 as of January 15, 2025.

Does Adaptimmune Therapeutics stock pay dividends?

No, Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Adaptimmune Therapeutics dividend payment date?

Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders.

What is the beta indicator for Adaptimmune Therapeutics?

Adaptimmune Therapeutics (ADAP) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.